<DOC>
	<DOCNO>NCT00928486</DOCNO>
	<brief_summary>To evaluate safety efficacy lenalidomide dexamethasone Japanese patient previously treat multiple myeloma .</brief_summary>
	<brief_title>A Safety Confirmation Study Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Must understand voluntarily sign informed consent form Age ≥ 20 year time signing informed consent form Subjects previously treat multiple myeloma define follow : Subjects must receive least 1 prior antimyeloma drug treatment regimen ; Considered progression disease ( PD ) occur either follow completion last antimyeloma treatment regimen utilized prior enrollment study Measurable level Mprotein serum ( great equal 0.5 g/dL [ 5g/L ] ) urine ( great equal 0.2 g excrete 24hour collection sample ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Must able adhere study visit schedule protocol requirement Females childbearing potential ( FCBP ) must agree use one follow form contraception abstain heterosexual contact completely male partner use condom occasion heterosexual contact follow period : For least 28 day start study drug ( particular , subject must abstain heterosexual contact 2 week prior prescribe lenalidomide ) . During treatment phase ( include dose withholding period ) For least 28 day discontinuation/completion study drug ( Methods contraception ) Birth control pill Intrauterine device ( IUD ) Bilateral tubal ligation ( FCBP must refer health care provider familiar contraceptive method , need ) . Male subject must agree use condom sexual contact female irrespective pregnancy potential Subjects must agree study drug must immediately discontinue , pregnancy positive pregnancy test occur female study subject partner male study subject study participation Pregnant lactating female Subjects history acute myocardial infarction within past 6 month start study drug Subjects history concurrent condition deep vein thrombosis pulmonary embolus within past 3 year start study drug Subjects tuberculous disease , herpes simplex keratitis , systemic mycosis active infectious disease Subjects noncontrolled diabetes , hypertension , digestive ulcer glaucoma Subjects posterior subcapsular cataract Subjects peripheral neuropathy ≥Grade 2 Subjects history concurrent condition Principal Investigator / subinvestigators consider inappropriate participation study , subject serious disease mental disease , consider become risky subject participate study . Subjects history desquamative ( blister ) rash take thalidomide Subjects history use lenalidomide Subjects use thalidomide within 28 day start study drug Subjects history hypersensitivity dexamethasone Subjects discontinue treatment due grade 3 4 toxicity high dose dexamethasone Subjects surgical wind visceral surgery perform recently Subjects undergone radiation therapy within 14 day start study drug Subjects use chemotherapeutic agent , immunomodulating agent study drug ( drug commercially available ) intend treatment multiple myeloma ( MM ) within 28 day start study drug Subjects history concurrent condition malignancy , MM , unless subject free disease 3 year : Basal cell carcinoma skin , Squamous cell carcinoma skin , Carcinoma situ cervix , Carcinoma situ breast , Incidental histologic find prostate cancer Tumor , Lymph Nodes , Metastasis ( TNM ) stage T1a T1b ) Known human immunodeficiency virus ( HIV ) infection HIV1 positivity Subjects diagnose hepatitis b virus ( HBV ) carrier Subjects applicable follow abnormal laboratory finding : Absolute neutrophil count : &lt; 1,000 /μL ( 1.0×10^9 /L ) Platelet count : &lt; 75,000 /μL ( 75×10^9 /L ) Aspartate aminotransferase ( AST ) /serum glutamic oxaloacetic transaminase ( SGOT ) alanine aminotransferase ( ALT ) /serum glutamicpyruvic transaminase ( SGPT ) : &gt; 3.0 time upper limit standard range Creatinine clearance : &lt; 30 mL/min</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>